What are the key challenges in the pharmacological management of cholangiocarcinoma?
作者信息
Ledenko Matthew, Patel Tushar
机构信息
Department of Transplantation, Mayo Clinic Florida, Jacksonville, Florida, USA.
出版信息
Expert Opin Pharmacother. 2022 Apr;23(5):531-533. doi: 10.1080/14656566.2021.2010707. Epub 2021 Dec 6.
Abstract
摘要
相似文献
1
What are the key challenges in the pharmacological management of cholangiocarcinoma?胆管癌药物治疗管理中的关键挑战有哪些？
Expert Opin Pharmacother. 2022 Apr;23(5):531-533. doi: 10.1080/14656566.2021.2010707. Epub 2021 Dec 6.
2
Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.转移性胆道癌的系统治疗：现状与未来展望。
Curr Oncol. 2022 Jan 27;29(2):551-564. doi: 10.3390/curroncol29020050.
3
The future is here-targeted therapies are coming of age in biliary tract cancers.未来已来——靶向治疗在胆管癌领域正走向成熟。
Chin Clin Oncol. 2023 Jun;12(3):20. doi: 10.21037/cco-23-20. Epub 2023 May 15.
4
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?双 HER2 阻断：转移性胆道癌的新选择？
Medicina (Kaunas). 2021 Nov 27;57(12):1301. doi: 10.3390/medicina57121301.
5
Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?胆管癌中的分子改变：是否是精准医疗的时代？
Liver Int. 2019 May;39 Suppl 1:32-42. doi: 10.1111/liv.14085. Epub 2019 Mar 24.
6
Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.胆管癌的全身治疗：从化疗到靶向治疗。
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):345-53. doi: 10.1016/j.bpg.2015.01.002. Epub 2015 Feb 19.
7
Immunotherapy in Biliary Tract Cancers: Where Are We?胆管癌的免疫治疗：我们在哪里？
Curr Oncol Rep. 2022 Dec;24(12):1821-1828. doi: 10.1007/s11912-022-01328-7. Epub 2022 Oct 4.
8
The state of therapy modalities in clinic for biliary tract cancer.胆道癌临床治疗方法的现状。
Front Biosci (Landmark Ed). 2022 Jun 8;27(6):185. doi: 10.31083/j.fbl2706185.
9
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).帕尼单抗联合吉西他滨和奥沙利铂不能延长野生型KRAS晚期胆管癌患者的生存期：一项随机2期试验（Vecti-BIL研究）
Cancer. 2016 Feb 15;122(4):574-81. doi: 10.1002/cncr.29778. Epub 2015 Nov 5.
10
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?胆管癌的化疗耐药和靶向治疗耐药：我们学到了什么？
Expert Opin Investig Drugs. 2022 Feb;31(2):221-233. doi: 10.1080/13543784.2022.2034785. Epub 2022 Feb 7.
本文引用的文献
1
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.晚期胆管癌二线FOLFOX化疗与积极症状控制的对比研究（ABC-06）：一项3期、开放标签、随机对照试验
Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.
2
Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.仑伐替尼单药二线治疗不可切除的胆道癌的 2 期研究：主要分析结果。
BMC Cancer. 2020 Nov 16;20(1):1105. doi: 10.1186/s12885-020-07365-4.
3
Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.达拉非尼联合曲美替尼治疗携带 BRAF 突变的胆道癌患者（ROAR）：一项 2 期、开放标签、单臂、多中心篮子试验。
Lancet Oncol. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17.
4
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.在晚期实体瘤患者中进行的 Futibatinib（一种高度选择性、不可逆的 FGFR1-4 抑制剂）的 I 期首次人体研究。
Ann Oncol. 2020 Oct;31(10):1405-1412. doi: 10.1016/j.annonc.2020.06.018. Epub 2020 Jul 2.
5
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020：机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
6
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.regorafenib 治疗局部晚期/转移性胆道肿瘤gemcitabine 和铂类化疗失败后的疗效：REACHIN，一项随机、双盲、II 期试验。
Ann Oncol. 2020 Sep;31(9):1169-1177. doi: 10.1016/j.annonc.2020.05.018. Epub 2020 May 25.
7
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
8
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.随机 II 期试验（SWOG S1310）：单一 MEK 抑制剂曲美替尼对比氟尿嘧啶或卡培他滨治疗难治性晚期胆道癌。
Eur J Cancer. 2020 May;130:219-227. doi: 10.1016/j.ejca.2020.01.026. Epub 2020 Mar 29.
9
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.培米替尼治疗既往治疗过的局部晚期或转移性胆管癌：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2020 May;21(5):671-684. doi: 10.1016/S1470-2045(20)30109-1. Epub 2020 Mar 20.
10
Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).辅助化疗 S-1 治疗淋巴结阳性胆道癌（N-SOG 09）的 2 期临床试验。
Ann Surg Oncol. 2020 Jul;27(7):2348-2356. doi: 10.1245/s10434-020-08355-3. Epub 2020 Mar 16.
Zotero 插件